Local biotech begins testing on skin graft technology

Madison-based Stratatech has begun Phase I testing for its wound-healing skin tissue on humans affected by diabetic foot ulcers.

According to a story in the Wisconsin State Journal, the company’s skin substitute, ExpressGraft C9T1, will be applied to up to six diabetic patients with foot issues and checked after a year.

Stratatech, which was purchased by London-based Mallinckrodt in 2016, is also testing a wound-healing skin replacement for severe burns called StrataGraft.